Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan

References

• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–23. discussion ii4-5.
   PubMed Web of Science ®Google Scholar
• de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140–7.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
   PubMed Web of Science ®Google Scholar
• Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5.
   Web of Science ®Google Scholar
• Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5–21.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–92.
   PubMed Web of Science ®Google Scholar
• Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102.
   PubMed Web of Science ®Google Scholar
• Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7–15.
   PubMed Web of Science ®Google Scholar
• Eisai. Fully human monoclonal anti-tnf-alpha antibody humira® receives approval as japan’s first biological agent for psoriasis; [Accessed November 2016]. Available from: http://www.eisai.com/news/news201005.html.
   Google Scholar
• Mitsubishi Tanabe Pharma. Remicade; [Accessed November 2016]. Available from: http://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC_REC120508_2.pdf.
   Google Scholar
• Adis Insight. Ustekinumab; [Accessed November 2016]. Available from: http://adisinsight.springer.com/drugs/800018418.
   Google Scholar
• HCP Live M. Secukinumab approved in japan for the treatment of plaque psoriasis and psoriatic arthritis; [Accessed November 2016]. Available from: http://www.hcplive.com/medical-news/secukinumab-approved-in-japan-for-the-treatment-of-plaque-psoriasis-and-psoriatic-arthritis.
   Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40:683–95.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iinuma S, Tsuji H, et al. Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol. 2014;41:686–9.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (pasi) and the dermatology life quality index (dlqi): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333–7.
   PubMed Web of Science ®Google Scholar
• Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24:52–7.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, de la Cueva P, Herranz P, et al. Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. J Dermatolog Treat. 2017;28:188–99.
   PubMed Web of Science ®Google Scholar
• Japanese National Health Insurance. National health insurance fee schedule; [Accessed November 2016]. Available from: http://www.iryohoken.go.jp/shinryohoshu.
   Google Scholar
• OECD. Stats; [Accessed November 2016]. Available from: http://stats.oecd.org/.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 1: Introduction. Med Decis Making. 2013;33:597–606.
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1–134.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ispor task force on indirect treatment comparisons good research practices: Part 2. Value Health. 2011;14:429–37.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ispor task force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417–28.
   PubMed Web of Science ®Google Scholar
• Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology (Basel). 2009;219:209–18.
   PubMed Web of Science ®Google Scholar
• Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch Dermatol. 2012;148:1403–10.
   PubMedGoogle Scholar
• Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29:620–34.
   PubMed Web of Science ®Google Scholar
• Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166:179–88.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Betts KA, Yan YS, et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol. 2015;172:504–12.
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10:1–233.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kuwabara H, Fahrbach K, et al. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in japan. J. Dermatolog Treat. 2013;24:351–5.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Report by the decision support unit; [Accessed 2016 September]. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0088912/pdf/PubMedHealth_PMH-0088912.pdf.
   Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in japanese patients with moderate-to-severe plaque psoriasis: subanalysis from erasure, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41:1039–46.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Japanese Infliximab Study i. Infliximab monotherapy in japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–9.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase ii/iii randomized controlled study. J Dermatol. 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242–52.
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261–73.
   PubMed Web of Science ®Google Scholar